RANEXA (ranolazine) is available as a film-coated, non-scored, extended-release tablet for oral administration.
RANEXA® is indicated for the treatment of chronic angina.
RANEXA may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
Media Articles Related to Ranexa (Ranolazine)
Mortality Down for Healthier Surgery Patients: Anesthesiology News Report
Source: MedPage Today Cardiology [2017.04.19]
(MedPage Today) -- Also, tranexamic acid may be safe after all in cardiac surgery
Published Studies Related to Ranexa (Ranolazine)
Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic
stable angina according to baseline hemoglobin A1c. 
efficacy of ranolazine was influenced by glycemic control... CONCLUSION: Among patients with T2DM and stable angina, the therapeutic benefits
Use of ranolazine in patients with incomplete revascularization after
percutaneous coronary intervention: design and rationale of the Ranolazine for
Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention
(RIVER-PCI) trial. 
CONCLUSIONS: RIVER-PCI is a novel, large-scale, international, randomized,
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic
stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes
Evaluation of Ranolazine in Subjects With Chronic Stable Angina). 
angina... CONCLUSIONS: Among patients with diabetes and chronic angina despite treatment
Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. [2011.05]
OBJECTIVES: We conducted a pilot study for a large definitive clinical trial evaluating the impact of ranolazine in women with angina, evidence of myocardial ischemia, and no obstructive coronary artery disease (CAD). BACKGROUND: Women with angina, evidence of myocardial ischemia, but no obstructive CAD frequently have microvascular coronary dysfunction. The impact of ranolazine in this patient group is unknown... CONCLUSIONS: In women with angina, evidence of ischemia, and no obstructive CAD, this pilot randomized, controlled trial revealed that ranolazine improves angina. Myocardial ischemia may also improve, particularly among women with low CFR. These data document approach feasibility and provide outcome variability estimates for planning a definitive large clinical trial to evaluate the role of ranolazine in women with microvascular coronary dysfunction. (Microvascular Coronary Disease In Women: Impact Of Ranolazine; NCT00570089). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. [2010.08.03]
CONCLUSIONS: Nonsustained VT is common after admission for non-ST-elevation acute coronary syndrome, and even short episodes of VT lasting 4 to 7 beats are independently associated with the risk of SCD over the subsequent year. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00099788.
Clinical Trials Related to Ranexa (Ranolazine)
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients [Completed]
End-stage renal disease (ESRD) patients often develop cardiovascular complications, and
cardiovascular disease is the leading cause of death in this population. Ranolazine's
ability to treat angina without reducing heart rate or blood pressure makes it an important
option for ESRD patients. The hemodialysis clearance of ranolazine is unknown. A single-dose
pharmacokinetic study is needed to characterize ranolazine and its metabolites in ESRD
patients on and off hemodialysis. Results of the proposed study will provide initial dosing
estimates for a follow-up, multiple-dose pharmacokinetic study in this population.
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY) [Completed]
The purpose of this study is to evaluate whether treatment with ranolazine or low dose
dronedarone reduces atrial fibrillation burden (AFB) in subjects with paroxysmal atrial
fibrillation (PAF), and whether combination therapy (ranolazine and low dose dronedarone) is
superior to individual drug therapy in reducing AFB.
This phase 2 clinical trial will be conducted over 16 weeks and involves a Screening period
(4 weeks) and a Treatment period (12 weeks). The final follow up visit will occur 2 weeks
after the end of the Treatment period. Primary and Secondary endpoints will be evaluated
according to treatment group, clinic visit period, and the overall Treatment period. Safety
analyses will be conducted at each clinic visit, and include: cardiac rhythm monitoring, ECG
testing, laboratory evaluation, and symptom and adverse event assessment.
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion [Completed]
Dose-ranging Phase II study testing the efficacy and safety of 3 doses of Ranolazine (low,
intermediate and high, given BID) versus placebo in maintaining sinus rhythm after
successful electrical cardioversion in patients with persistent atrial fibrillation (AFib).
After successful cardioversion and subsequent randomisation, patients report
trans-telephonic EGCs on a daily basis to a central core ECG facility.
Maximum treatment duration is 112 days (16 weeks).
Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP) [Recruiting]
The purpose of this trial is to determine if patients suffering from diabetic peripheral
neuropathic pain treated with ranolazine will have a greater reduction in pain compared to
Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical
animal model of neuropathic pain, the investigators hypothesize that subjects randomized to
ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo.
Ranolazine in Ischemic Cardiomyopathy [Completed]
Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and
shortness of breath despite conventional medical therapy and/or revascularization. The
purpose of this study is to determine the efficacy of taking Ranexa versus placebo in
patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional
medical therapy and/or percutaneous revascularization.
Reports of Suspected Ranexa (Ranolazine) Side Effects
Drug Interaction (6),
Chest Pain (6),
Renal Failure Acute (6),
Confusional State (5),
Transaminases Increased (4), more >>
Page last updated: 2017-04-19